Sarah R. Levi

Sarah R. Levi

Auto-generated profile, based on publicly available information

Sarah R. Levi

Jonas Children's Vision Care, and Bernard & Shirlee Brown Glaucoma Laboratory, Columbia Stem Cell Initiative, Department of Ophthalmology, Department of Pathology, Department of Cell Biology, Institute of Human Nutrition, Columbia University, New York, NY, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
Eugene Yu-Chuan KangEugene Yu-Chuan Kang
Eugene Yu-Chuan Kang
PLPei-Kang Liu
Pei-Kang Liu
YWYao-Tseng Wen
Yao-Tseng Wen
Peter M.J. QuinnPeter M.J. Quinn
Peter M.J. Quinn
SLSarah R. Levi
Sarah R. Levi
RTRong-Kung Tsai
Rong-Kung Tsai
Ocular diseases associated with retinal ganglion cell (RGC) degeneration is the most common neurodegenerative disorder that causes irreversible blindness worldwide. It is characterized by visual field defects and progressive optic nerve atrophy. The underlying pathophysiology and mechanisms of RGC degeneration in several ocular diseases remain largely unknown. RGCs are a population of central nervous system neurons, with their soma located in the retina and long axons that extend through the optic nerve to form distal terminals and connections in the brain. Because of this unique cytoarchitecture and highly compartmentalized energy demand, RGCs are highly mitochondrial-dependent for adenosine triphosphate (ATP) production. Recently, oxidative stress and mitochondrial dysfunction have been found to be the principal mechanisms in RGC degeneration as well as in other neurodegenerative disorders. Here, we review the role of oxidative stress in several ocular diseases associated with RGC degenerations, including glaucoma, hereditary optic atrophy, inflammatory optic neuritis, ischemic optic neuropathy, traumatic optic neuropathy, and drug toxicity. We also review experimental approaches using cell and animal models for research on the underlying mechanisms of RGC degeneration. Lastly, we discuss the application of antioxidants as a potential future therapy for the ocular diseases associated with RGC degenerations.

27 April 2020 in Mammalian Genome
Verified
Journal Article
Closed access
PDF file
EZEthan Zhang
Ethan Zhang
JRJoseph Ryu
Joseph Ryu
SLSarah R. Levi
Sarah R. Levi
JOJin Kyun Oh
Jin Kyun Oh
CHChun Wei Hsu
Chun Wei Hsu
STStephen Tsang
Stephen Tsang

Verified
Journal Article
Open access
PDF file
TCThiago Cabral
Thiago Cabral
JCJose Ronaldo Lima de Carvalho
Jose Ronaldo Lima de Carvalho
JKJoonpyo Kim
Joonpyo Kim
JOJin Kyun Oh
Jin Kyun Oh
SLSarah R. Levi
Sarah R. Levi
STStephen Tsang
Stephen Tsang
Retinitis pigmentosa (RP) is a category of inherited retinal dystrophies that is best prognosticated using electroretinography (ERG). In this retrospective cohort study of 25 patients with RP, we evaluated the correlation between 30 Hz flicker ERG and structural parameters in the retina. Internationally standardized 30 Hz flicker ERG recordings, short-wavelength autofluorescence (SW-AF), and spectral domain–optical coherence tomography (SD-OCT) were acquired at two visits at least one year apart. Vertical and horizontal hyperautofluorescent ring diameter measurements with SW-AF, as well as ellipsoid zone (EZ) line width measurements with SD-OCT, were used as structural parameters of disease progression. The 30 Hz flicker ERG amplitude decreased by 2.2 ± 0.8 µV/year (p = 0.011), while implicit times remained unchanged. For SD-OCT, the EZ line decreased by 204.1 ± 34.7 µm/year (p < 0.001). Horizontal and vertical hyperautofluorescent ring diameters decreased by 161.9 ± 25.6 µm/year and 146.9 ± 34.6 µm/year, respectively (p = 0.001), with SW-AF. A correlation was found between the progression rates of the 30 Hz flicker amplitude recorded with Burian–Allen electrodes and both the horizontal ring diameter (p = 0.020) and EZ line (p = 0.044). SW-AF and SD-OCT, two readily available imaging techniques, may be used to prognosticate disease progression because of the reliability of their measurements and correlation with functional outcome.

30 January 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
ACAhra Cho
Ahra Cho
JCJose Ronaldo Lima de Carvalho
Jose Ronaldo Lima de Carvalho
ATAkemi J. Tanaka
Akemi J. Tanaka
RJRuben Jauregui
Ruben Jauregui
SLSarah R. Levi
Sarah R. Levi
STStephen Tsang
Stephen Tsang
Whole exome sequencing (WES) allows for an unbiased search of the genetic cause of a disease. Employing it as a first-tier genetic testing can be favored due to the associated lower incremental cost per diagnosis compared to when using it later in the diagnostic pathway. However, there are technical limitations of WES that can lead to inaccurate negative variant callings. Our study presents these limitations through a re-evaluation of negative WES results using subsequent tests primarily driven by fundoscopic findings. These tests included targeted gene testing, inherited retinal gene panels, whole genome sequencing (WGS), and array comparative genomic hybridization. Subsequent genetic testing guided by fundoscopy findings identified the following variant types causing retinitis pigmentosa that were not detected by WES: frameshift deletion and nonsense variants in the RPGR gene, 353-bp Alu repeat insertions in the MAK gene, and large exonic deletion variants in the EYS and PRPF31 genes. Deep intronic variants in the ABCA4 gene causing Stargardt disease and the GUCY2D gene causing Leber congenital amaurosis were also identified. Negative WES analyses inconsistent with the phenotype should raise clinical suspicion. Subsequent genetic testing may detect genetic variants missed by WES and can make patients eligible for gene replacement therapy and upcoming clinical trials. When phenotypic findings support a genetic etiology, negative WES results should be followed by targeted gene sequencing, array based approach or whole genome sequencing.

21 May 2020 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
JOJin Kyun Oh
Jin Kyun Oh
JRJoseph Ryu
Joseph Ryu
JCJose Ronaldo Lima de Carvalho
Jose Ronaldo Lima de Carvalho
SLSarah R. Levi
Sarah R. Levi
WLWinston Lee
Winston Lee
STStephen Tsang
Stephen Tsang

1 August 2020 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
SLSarah R. Levi
Sarah R. Levi
JOJin Kyun Oh
Jin Kyun Oh
JCJose Ronaldo Lima de Carvalho
Jose Ronaldo Lima de Carvalho
VMVinit B. Mahajan
Vinit B. Mahajan
STStephen H. Tsang
Stephen H. Tsang
JSJanet Sparrow
Janet Sparrow
This case report details the 6-year follow-up of a patient treated with voretigene neparvovec gene therapy.